Clarence Ahlem
Director de Operaciones en NeurMedix, Inc. .
Fortuna: 18 165 $ al 30/04/2024
Perfil
Clarence Ahlem currently works at NeurMedix, Inc., as Chief Operating Officer.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0.07% | 16/02/2023 | 37 148 ( 0.07% ) | 18 165 $ | 30/04/2024 |
Cargos activos de Clarence Ahlem
| Empresas | Cargo | Inicio |
|---|---|---|
NeurMedix, Inc.
 NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Director de Operaciones | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
NeurMedix, Inc.
NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Health Technology |
- Bolsa de valores
- Insiders
- Clarence Ahlem
